Stock ESPR ESPERION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Comparison Chart Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
2.13 USD -5.33% Intraday chart for Esperion Therapeutics, Inc. -17.76% -28.76%
May. 22 Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events CI
May. 20 Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise MT
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

Compared values

Sector Change 5d. change 1st Jan change 1-year change 5-years change Capi. ST MT LT
ESPERION THERAPEUTICS, INC.
Other Pharmaceuticals
-5.33%-17.76%-28.76%+30.67%-95.82% 426M
Neutral
Neutral
Bullish

Technical Rankings Surperformance

  1. Stock Market
  2. Equities
  3. ESPR Stock
  4. Charts Esperion Therapeutics, Inc.
  5. Comparison Chart